MLYS
MLYS
NASDAQ · Biotechnology

Mineralys Therapeutics Inc

$29.26
+2.61 (+9.79%)
As of May 9, 1:28 AM ET ·
Analyst Consensus
Strong Buy
15
Analysts
High
Coverage
Buy 13 87%
Hold 2 13%
Sell 0 0%
Price Target
Analyst Price Target +218.5% upside
Low Target $50.31
Average Target $93.19
High Target $121.15
Current Price $29.26
Current
$29.26
Target
$93.19
$50.31 $93.19 avg $121.15
Scenario Analysis
Bear Case
$50.31
71.9%
Low target
Base Case
$93.19
+218.5%
Avg target
Bull Case
$121.15
+314.0%
High target
Risk/Reward
4.4x
Highly favorable
Price in Context
52-Week High
$47.65
-38.6% from high
52-Week Low
$12.59
+132.4% from low
50-Day SMA
$33.44
-12.5% vs SMA
200-Day SMA
$27.93
+4.8% vs SMA
RSI (14)
35.0
Neutral
Target vs 52W High
$93.19
+95.6% vs high
Next Earnings Report
May 18, 2026
8d
until earnings
EPS Est: $-0.47
Earnings in 8 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 39 72% $257.58 +27.8%
AMGN
Amgen Inc
Hold 43 49% $190.87 -42.5%
GILD
Gilead Sciences Inc
Strong Buy 39 79% $362.68 +176.2%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 +2.0%
REGN
Regeneron Pharmaceuticals
Strong Buy 38 79% $76.80 -89.3%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -65.3%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -19.5%
INSM
Insmed Inc
Strong Buy 26 96% $143.40 +41.5%